Monthly Archives: September 2011

Debunking Corporate Venture Capital in Biotech
September 25, 2011

Corporate venture capital’s rise to prominence in biotech over the past few years is now a well worn subject.  It was yet again debated this week at the Windhover PSA meeting, in part triggered by the recent widely-covered launch of

1 Comment

Billion Dollar Policy Ideas for Supporting Biotech Innovation
September 14, 2011

Amidst talk of the need for renewed economic stimulus and the desire for America to invest in innovative industries, I thought I’d highlight two practical tax policy ideas for how to accelerate biotech sector growth: enabling NOL tradability and creating

1 Comment

Our Shrinking Biopharma Ecosystem
September 9, 2011

The sustainability of the biopharma sector depends on a continual flow of new startups to both feed Big Pharma’s pipelines and to create the next generation of emerging mid-cap companies.  At the BioPharma America conference this week, several panelists asserted


Four Types of “Premature Scaling” in Biotech
September 2, 2011

Earlier this week the Startup Genome project released a report on the DNA of internet startups.  Essentially what attributes lead to success or failure.  One of the things they found was that 74% of startups failed because of “premature scaling”.